[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3442532A4 - Treatment of renal cell carcinoma with lenvatinib and everolimus - Google Patents

Treatment of renal cell carcinoma with lenvatinib and everolimus Download PDF

Info

Publication number
EP3442532A4
EP3442532A4 EP17782552.8A EP17782552A EP3442532A4 EP 3442532 A4 EP3442532 A4 EP 3442532A4 EP 17782552 A EP17782552 A EP 17782552A EP 3442532 A4 EP3442532 A4 EP 3442532A4
Authority
EP
European Patent Office
Prior art keywords
lenvatinib
everolimus
treatment
cell carcinoma
renal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17782552.8A
Other languages
German (de)
French (fr)
Other versions
EP3442532A1 (en
Inventor
Alton KREMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of EP3442532A1 publication Critical patent/EP3442532A1/en
Publication of EP3442532A4 publication Critical patent/EP3442532A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17782552.8A 2016-04-15 2017-04-17 Treatment of renal cell carcinoma with lenvatinib and everolimus Withdrawn EP3442532A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322916P 2016-04-15 2016-04-15
JP2016081787 2016-04-15
PCT/JP2017/015461 WO2017179739A1 (en) 2016-04-15 2017-04-17 Treatment of renal cell carcinoma with lenvatinib and everolimus

Publications (2)

Publication Number Publication Date
EP3442532A1 EP3442532A1 (en) 2019-02-20
EP3442532A4 true EP3442532A4 (en) 2019-12-11

Family

ID=60041779

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17782552.8A Withdrawn EP3442532A4 (en) 2016-04-15 2017-04-17 Treatment of renal cell carcinoma with lenvatinib and everolimus

Country Status (7)

Country Link
EP (1) EP3442532A4 (en)
KR (1) KR20180129795A (en)
CN (1) CN108883106A (en)
AU (1) AU2017249459A1 (en)
CA (1) CA3019682A1 (en)
SG (1) SG11201808774RA (en)
WO (1) WO2017179739A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793736A (en) * 2019-01-31 2019-05-24 徐州医科大学 Application of a kind of lenvatinib in the preparation of natural killer cell agonist
WO2021262562A2 (en) * 2020-06-17 2021-12-30 Merck Sharp & Dohme Corp. Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ547518A (en) * 2003-12-25 2009-06-26 Eisai R&D Man Co Ltd Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EISAI GMBH: "summary of product characteristics", 16 May 2021 (2021-05-16), pages 1 - 43, XP093107850, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/product-information/kisplyx-epar-product-information_en.pdf> *
EISAI: "EISAI ANNOUNCES NEW INVESTIGATIONAL DATA EVALUATING TKIMTOR INHIBITOR REGIMEN LENVIMA (LENVATINIB) PLUS EVEROLIMUS IN ADVANCED RENAL CELL CARCINOMA (RCC) AT IKCS", HUMAN HEALTH CARE, 7 November 2020 (2020-11-07), XP093107608, Retrieved from the Internet <URL:https://media-us.eisai.com/2020-11-07-Eisai-Announces-New-Investigational-Data-Evaluating-TKI-mTOR-Inhibitor-Regimen-LENVIMA-R-lenvatinib-Plus-Everolimus-in-Advanced-Renal-Cell-Carcinoma-RCC-at-IKCS-2020> [retrieved on 20231130] *
LEONETTI ALESSANDRO ET AL: "Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma", SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN THE TREATMENT OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE., vol. Volume 13, 1 June 2017 (2017-06-01), pages 799 - 806, XP093107244, ISSN: 1178-203X, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=37200> DOI: 10.2147/TCRM.S126910 *
No further relevant documents disclosed *
PAL SUMANTA K ET AL: "Phase 2 trial of Ienvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC)", THE 19TH ANNUAL MEETING OF THE INTERNATIONAL KIDNEY CANCER SYMPOSIUM, 1 December 2020 (2020-12-01), pages 31 - 35, XP093107604, Retrieved from the Internet <URL:https://www.kidneycancer.org/wp-content/uploads/2022/11/IKCS20-Abstract-Supplement_KidneyCancerJournal.pdf> [retrieved on 20231130] *
See also references of WO2017179739A1 *

Also Published As

Publication number Publication date
EP3442532A1 (en) 2019-02-20
AU2017249459A1 (en) 2018-10-25
CN108883106A (en) 2018-11-23
KR20180129795A (en) 2018-12-05
SG11201808774RA (en) 2018-11-29
CA3019682A1 (en) 2017-10-19
WO2017179739A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
EP3328399A4 (en) Modified cells and methods of therapy
EP3200915A4 (en) Biochars and biochar treatment processes
EP3253387A4 (en) Compounds and uses in treatment of senescence-associated conditons
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
EP3114716A4 (en) Battery cells and arrangements
EP3274720A4 (en) Integrated functional and molecular profiling of cells
EP3250682A4 (en) Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP3245303A4 (en) Age-modified cells and methods for making age-modified cells
EP3148526A4 (en) Use of eribulin in the treatment of cancer
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
EP3193875A4 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
EP3202909A4 (en) Cancer specific-splicing ribozyme and use thereof
EP3266803A4 (en) Polymer and crosslinked body thereof
EP3113766A4 (en) Fractionated radiotherapy and chemotherapy with an oxygen therapeutic
EP3226955A4 (en) Self-anchoring catheters and methods of use
EP3112395A4 (en) Porous coordination polymer and application therefor
EP3222721A4 (en) Novel precursor mirna and application thereof in tumor treatment
EP3124534A4 (en) Hnbr composition and hnbr crosslinked body
EP3102611A4 (en) Humanized beta-amyloid binding molecules and uses thereof
EP3163899A4 (en) Earphone fine-adjustment structure and earphone
AU2017267955B2 (en) Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
EP3494217A4 (en) Lmp1-expressing cells and methods of use thereof
EP3110902A4 (en) Well treatment methods and fluids
EP3439651A4 (en) Improvements in cancer treatment
EP3157524A4 (en) Methods of treating cancer and preventing cancer drug resistance

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191112

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20191106BHEP

Ipc: A61K 31/436 20060101ALI20191106BHEP

Ipc: A61P 35/00 20060101ALI20191106BHEP

Ipc: A61K 9/48 20060101ALI20191106BHEP

Ipc: A61K 31/47 20060101AFI20191106BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

18W Application withdrawn

Effective date: 20240614